LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Inicio・Lista de Acciones・Cara Therapeutics Inc

Cara Therapeutics Inc

Cerrado

Sector Salud

0.29 -6.45

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

0.29

Máximo

0.31

Métricas clave
By Trading Economics
Ingresos	-28M
Ventas	-1.9M 3M
BPA	-0.59
Margen de beneficio	-576.079
Empleados	55
EBITDA	-29M

Recomendaciones
By TipRanks
Recomendaciones	Neutral
Estimación a 12 meses	+212.5 upside

Dividendos
By Dow Jones
Próximas Ganancias	11 nov 2024

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	-2.3M 46M
Apertura anterior	6.74
Cierre anterior	0.29

Noticias sobre sentimiento de mercado

By Acuity

79%

21%

321 / 365 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

0.3145 / 0.36 Soporte y Resistencia

Cara Therapeutics Inc Gráfico

Noticias Relacionadas

6 sept 2024, 22:41 UTC

Charlas de Mercado

KinderCare and StandardAero File for IPOs -- Market Talk

6 sept 2024, 21:18 UTC

Principales Noticias

Hiring Softened This Summer, Teeing Up Fed Rate Cuts -- Update

6 sept 2024, 21:05 UTC

Principales Noticias

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- 4th Update

6 sept 2024, 20:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

6 sept 2024, 20:39 UTC

Ganancias

Update: NIO Stock Caught an Upgrade. Shares Rose. -- Barrons.com

6 sept 2024, 20:35 UTC

Principales Noticias

Stocks Extend Ugly Week of Losses Amid Economic Uncertainty -- WSJ

6 sept 2024, 20:34 UTC

Principales Noticias

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- 3rd Update

6 sept 2024, 20:11 UTC

Principales Noticias

Stock Indexes Close Lower After Mixed Jobs Report -- WSJ

6 sept 2024, 19:51 UTC

Principales Noticias

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- WSJ

6 sept 2024, 19:16 UTC

Charlas de Mercado

U.S. Natural Gas Futures Hold Gains -- Market Talk

6 sept 2024, 19:14 UTC

Charlas de Mercado

Oil Futures Extend Losses on Demand Concerns -- Market Talk

6 sept 2024, 19:01 UTC

Charlas de Mercado

Gold Slips on Prevailing Uncertainty -- Market Talk

6 sept 2024, 18:27 UTC

Principales Noticias

JPMorgan Plans to Report Customers Who Exploited TikTok 'Glitch' to Authorities -- WSJ

6 sept 2024, 18:25 UTC

Charlas de Mercado

Broadcom Growth Views Conservative Amid AI Investments -- Market Talk

6 sept 2024, 18:15 UTC

Principales Noticias

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- Update

6 sept 2024, 18:12 UTC

Principales Noticias

Nasdaq Falls 2.5%, Leads Losses After Mixed Jobs Report -- WSJ

6 sept 2024, 17:44 UTC

Charlas de Mercado

Labor Costs Represent Diminishing Risk To Canada CPI, CIBC's Shenfeld Says -- Market Talk

6 sept 2024, 17:30 UTC

Charlas de Mercado

U.S Oil Rig Count Unchanged at 483 -- Market Talk

6 sept 2024, 17:30 UTC

Principales Noticias

Boeing's Starliner Is Returning to Earth Without Its Crew -- WSJ

6 sept 2024, 17:27 UTC

Principales Noticias

Hiring Softened This Summer, Teeing Up Fed Rate Cuts -- WSJ

6 sept 2024, 17:00 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

6 sept 2024, 17:00 UTC

Charlas de Mercado

Mexican Inflation Seen Easing in August -- Market Talk

6 sept 2024, 16:36 UTC

Charlas de Mercado

Oil Futures Fall as U.S. Jobs Report Sinks In -- Market Talk

6 sept 2024, 16:35 UTC

Ganancias

Acciones populares

Stocks to Watch Friday: Broadcom, Nvidia, UiPath, Smith & Wesson -- WSJ

6 sept 2024, 16:33 UTC

Adquisiciones, fusiones, absorciones

Salesforce Stock Is on Pace for Longest Losing Streak Since 2008. An Acquisition Isn't Helping. -- Barrons.com

6 sept 2024, 16:20 UTC

Charlas de Mercado

Ganancias

Tech, Media & Telecom Roundup: Market Talk

6 sept 2024, 16:20 UTC

Ganancias

Oracle Profit, Revenue Set to Rise in 1Q -- Earnings Preview

6 sept 2024, 16:20 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

6 sept 2024, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

6 sept 2024, 16:20 UTC

Charlas de Mercado

Energy & Utilities Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Cara Therapeutics Inc Esperado

Precio Objetivo

By TipRanks

212.5% repunte

Estimación a 12 meses

Media 1 USD 212.5%

Máximo 1 USD

Mínimo 1 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Cara Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

3 ratings

Comprar

Mantener

Vender

De acuerdo con 3 analistas que ofrecen calificaciones bursátiles a para Cara Therapeutics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

0.3145 / 0.36Soporte y Resistencia

Recent bearish events outweigh bullish events.

There are no events.

Sentimiento

By Acuity

321 / 365 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

EBITDA

Beneficio operativo

Acerca de Cara Therapeutics Inc

Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). The Company is developing a class of product candidates KORSUVA (CR845/difelikefalin), which is a KOR agonist that targets the body’s peripheral nervous system, as well as certain immune cells. The Company is also conducting preclinical studies and clinical trials of CR845/difelikefalin-based product candidates.